Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-86.
 Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-97.
 Ekhteraei-Tousi S, Mohammad-Soltani B, Sadeghizadeh M, et al. Inhibitory effect of hsa-miR-590-5p on cardiosphere-derived stem cells differentiation through downregulation of TGFB signaling[J]. J Cell Biochem, 2015, 116(1): 179-91.
 Lee S, Yu K R, Ryu Y S, et al. miR-543 and miR-590-3p regulate human mesenchymal stem cell aging via direct targeting of AIMP3/p18[J]. Age (Dordr), 2014, 36(6): 9724.
 Li Y, Sarkar F H. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer[J]. Int J Biol Sci, 2016, 12(3): 326-37.
 Feng Z Y, Xu X H, Cen D Z, et al. miR-590-3p promotes colon cancer cell proliferation via Wnt/beta-catenin signaling pathway by inhibiting WIF1 and DKK1[J]. Eur Rev Med Pharmacol Sci, 2017, 21(21): 4844-4852.
 Zhou C, Li J, Li J, et al. Hsa-miR-137, hsa-miR-520e and hsa-miR-590-3p perform crucial roles in Lynch syndrome[J]. Oncol Lett, 2016, 12(3): 2011-2017.
 Pang H, Zheng Y, Zhao Y, et al. miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2[J]. Biochem Biophys Res Commun, 2015, 468(4): 739-45.
 Hong L, Zhao X, Shao X, et al. miR-590 regulates WT1 during proliferation of G401 cells[J]. Mol Med Rep, 2017, 16(1): 247-253.
 Soos T J, Kiyokawa H, Yan J S, et al. Formation of p27-CDK complexes during the human mitotic cell cycle[J]. Cell Growth Differ, 1996, 7(2): 135-46.
 Juuti A, Nordling S, Louhimo J, et al. Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer[J]. Oncology, 2003, 65(4): 371-7.
 Lu C D, Morita S, Ishibashi T, et al. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma[J]. Cancer, 1999, 85(6): 1250-60.
 Feakins R M, Ghaffar A H. p27 Kip1 expression is reduced in pancreatic carcinoma but has limited prognostic value[J]. Hum Pathol, 2003, 34(4): 385-90.
 Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling[J]. Biochem J, 2001, 353(Pt 3): 417-39.
 Lechward K, Awotunde O S, Swiatek W, et al. Protein phosphatase 2A: variety of forms and diversity of functions[J]. Acta Biochim Pol, 2001, 48(4): 921-33.
 Zhang J, Jin M, Chen X, et al. Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer[J], 2018, 51(4): e12444.
 Sun Z Q, Shi K, Zhou Q B, et al. MiR-590-3p promotes proliferation and metastasis of colorectal cancer via Hippo pathway[J]. Oncotarget, 2017, 8(35): 58061-58071.
 Salem M, O'brien J A. miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway[J], 2018, 78(15): 4175-4190.
 Salem M, Shan Y, Bernaudo S, et al. miR-590-3p Targets Cyclin G2 and FOXO3 to Promote Ovarian Cancer Cell Proliferation, Invasion, and Spheroid Formation[J]. Int J Mol Sci, 2019, 20(8).
 Lorenz W W, Mccann R O, Longiaru M, et al. Isolation and expression of a cDNA encoding Renilla reniformis luciferase[J]. Proc Natl Acad Sci U S A, 1991, 88(10): 4438-42.
 Farr A, Roman A. A pitfall of using a second plasmid to determine transfection efficiency[J]. Nucleic Acids Res, 1992, 20(4): 920.
 Wingate H, Zhang N, Mcgarhen M J, et al. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27[J]. J Biol Chem, 2005, 280(15): 15148-57.
 Sarkar S, Dubaybo H, Ali S, et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA[J]. Am J Cancer Res, 2013, 3(5): 465-77.
 Li Z, Tao Y, Wang X, et al. Tumor-Secreted Exosomal miR-222 Promotes Tumor Progression via Regulating P27 Expression and Re-Localization in Pancreatic Cancer[J]. Cell Physiol Biochem, 2018, 51(2): 610-629.
 Wang Q, Li J, Wu W, et al. Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer[J]. Oncotarget, 2016, 7(10): 11208-22.
 Shen R, Wang Q, Cheng S, et al. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models[J]. Cancer Lett, 2013, 339(1): 135-43.
 Beca F, Pereira M, Cameselle-Teijeiro J F, et al. Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer[J]. BMC Cancer, 2015, 15: 285.
 Shouse G, De Necochea-Campion R, Mirshahidi S, et al. Novel B55alpha-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest[J]. Oncotarget, 2016, 7(38): 61081-61092.
 Ruvolo P P, Ruvolo V R, Jacamo R, et al. The protein phosphatase 2A regulatory subunit B55alpha is a modulator of signaling and microRNA expression in acute myeloid leukemia cells[J]. Biochim Biophys Acta, 2014, 1843(9): 1969-77.
 Wong Q W, Ching A K, Chan A W, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling[J]. Clin Cancer Res, 2010, 16(3): 867-75.
 Zhang J, Gao D, Zhang H. Upregulation of miR-614 promotes proliferation and inhibits apoptosis in ovarian cancer by suppressing PPP2R2A expression[J]. Mol Med Rep, 2018, 17(5): 6285-6292.
 Liang W L, Cao J, Xu B, et al. miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells[J]. Biomed Pharmacother, 2015, 72: 119-24.